Home›Screener›DSGN›Profile
D
37/100

Design Therapeutics

DSGNRare Disease
← Signals View
📋
Analyst Summary
✓ VERIFIED2026-04-11

Design Therapeutics (DSGN) is the lead sponsor of 2 active clinical trials listed on ClinicalTrials.gov[3], including 2 Phase 2[1], 1 Phase 1[2].

DSGN has 1 Form 4 insider filing recorded at the SEC in the past 30 days[4].

Sources

  1. ClinicalTrials.gov (2026-04-11) ↗
  2. ClinicalTrials.gov (2026-04-11) ↗
  3. ClinicalTrials.gov (2026-04-11) ↗
  4. SEC EDGAR · 0001807120 (2026-04-11) ↗
🔬
Clinical Trials
2
NCT06874010Friedreich Ataxia
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT07024693Fuchs Endothelial Corneal Dystrophy, Fuchs
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
👤
Insider Activity
1
1 filing
Source ↗
sec_edgar · Retrieved 2026-04-11
Not financial advice. BiotechSigns profiles are AI-generated from verified public sources (ClinicalTrials.gov, SEC EDGAR) and are for informational purposes only. Always do your own due diligence before making investment decisions.
Score Breakdown
Score Trend
2026-04-132026-06-02
Signal Summary
PDUFA Dates0
Insider Filings1
Clinical Trials1
Sector Peers (Rare Disease)
AGIOAgios Pharmaceuticals
A
RETAReata Pharmaceuticals
C
RAREUltragenyx Pharmaceutical
C
FOLDAmicus Therapeutics
C
STOKStoke Therapeutics
D
Data Provenance
cik1 verified
clinical trial2 verified
insider buy1 verified
trial count3 verified
Every claim backed by source URL from ClinicalTrials.gov or SEC EDGAR